Zirconium-89-girentuximab PET/CT imaging in patients suspected of primary or relapse clear cell renal cell carcinoma: The impact on clinical decision making

Completed

• Conditions: renal cancer; 10038364

• Registration Number: NL-OMON42374
• Lead Sponsor: Radboud Universitair Medisch Centrum

Brief Summary

Trial is onging in other countries

Detailed Description

Not available

Study Timeline

• Study Completion: 2017-06-06
• Last Update Posted: 23 April 2024

Recruitment & Eligibility

• Status: Completed
• Sex: Not specified
• Target Recruitment: 30

Inclusion Criteria

His or her clinician should face a diagnostic dilemma;
- patients with a renal mass of unknown origin, or
- patients with a primary renal mass in whom it is unclear whether there is metastatic disease, or
- patients with a history of clear cell RCC with a suspicion of relapse or metastatic disease.
*
Age over 18 years;Signed informed consent

Exclusion Criteria

History of a CAIX-negative or non clear cell RCC.
Administration of tyrosine kinase inhibiters within 1 month prior to inclusion.
Known hypersensitivity or HACA against Girentuximab.

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>Impact on clinical decision making, defined as present or absent:<br /><br>* Absent: e.g. no change in treatment or follow-up<br /><br>* Present: e.g. change in follow-up schedule, change in surgical technique, be<br /><br>more certain of your treatment strategy, change from surgery to active<br /><br>surveillance, or change from surgery to systemic treatment.</p><br>

Secondary Outcome Measures

Name	Time	Method
<p>The amount of biopsies or surgery that are prevented by<br /><br>zirconium-89-girentuximab PET/CT.<br /><br>*</p><br>